Courtesy bossman lse6 Jul 2019 22:18
For all the guys over on Lse.co.uk who asking about Efficacy for val201 assuming that they can all read...lol
Dr Satu Vainikka, CEO of ValiRx, commented: "VAL201 has demonstrated disease stabilisation, with a lower dose than was predicted by our preclinical evaluations. We anticipate that by increasing the dosage we will show a high level of efficacy without compromising the safety and tolerability shown to date to meet the needs of those patients currently under-served by current therapies. ValiRx is entering a very exciting phase, which should result in the crystallisation of substantial value"
VAL201 is unlike current therapies for advanced prostate cancer, which often include androgen deprivation. VAL201 is intended to target a specific pathway from the androgen receptor, treating the cancer without suppressing sexual and other functions and without many other debilitating side effects many therapies have.